Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer : a case report
2024 Translational Lung Cancer Research. All rights reserved..
Background: Hyperprogressive disease is an unexpected response pattern observed in immune checkpoint therapy and associated with poor prognosis. The rechallenge of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors can be a treatment option in non-small cell lung cancer (NSCLC) patients who once responded to them. Here, we reported the hyperprogressive phenomenon after PD-1/PD-L1 rechallenge in a patient with NSCLC.
Case Description: This case report described a patient with recurrent large cell lung cancer undergoing hyperprogressive disease with pleural and pericardial dissemination shortly after the pembrolizumab rechallenge, although he had a favorable response to the initial pembrolizumab treatment. A lower ratio of CD8+ T cells to Foxp3+ regulatory T cells was distributed in the cell blocks of pleural and pericardial effusion which were taken after hyperprogressive disease, compared to the resected tumor microenvironment. Neutrophil-to-lymphocyte ratio (NLR) was lower in peripheral blood when the disease was controlled and it rose when the disease progressed. Notably, NLR increased dramatically when hyperprogression occurred.
Conclusions: For the first time, we reported that a patient who showed a favorable response to initial anti-PD-1 treatment underwent hyperprogressive disease when rechallenging the same immunotherapy. The increased Foxp3+ regulatory T cells in the tumor microenvironment and the longitudinal change of NLRs in peripheral blood were suggested to be associated with hyperprogressive disease.
| Medienart: |
E-Artikel |
|---|
| Erscheinungsjahr: |
2024 |
|---|---|
| Erschienen: |
2024 |
| Enthalten in: |
Zur Gesamtaufnahme - volume:13 |
|---|---|
| Enthalten in: |
Translational lung cancer research - 13(2024), 3 vom: 29. März, Seite 666-672 |
| Sprache: |
Englisch |
|---|
| Beteiligte Personen: |
Xu, Shiting [VerfasserIn] |
|---|
| Links: |
|---|
| Themen: |
Anti-programmed cell death 1 rechallenge (anti-PD-1 rechallenge) |
|---|
| Anmerkungen: |
Date Revised 12.04.2024 published: Print-Electronic Citation Status PubMed-not-MEDLINE |
|---|
| doi: |
10.21037/tlcr-23-765 |
|---|
| funding: |
|
|---|---|
| Förderinstitution / Projekttitel: |
|
| PPN (Katalog-ID): |
NLM370907620 |
|---|
| LEADER | 01000caa a22002652 4500 | ||
|---|---|---|---|
| 001 | NLM370907620 | ||
| 003 | DE-627 | ||
| 005 | 20240412233554.0 | ||
| 007 | cr uuu---uuuuu | ||
| 008 | 240411s2024 xx |||||o 00| ||eng c | ||
| 024 | 7 | |a 10.21037/tlcr-23-765 |2 doi | |
| 028 | 5 | 2 | |a pubmed24n1373.xml |
| 035 | |a (DE-627)NLM370907620 | ||
| 035 | |a (NLM)38601437 | ||
| 040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
| 041 | |a eng | ||
| 100 | 1 | |a Xu, Shiting |e verfasserin |4 aut | |
| 245 | 1 | 0 | |a Hyperprogressive disease under anti-PD-1 rechallenge after initial response to anti-PD-1 treatment for non-small cell lung cancer |b a case report |
| 264 | 1 | |c 2024 | |
| 336 | |a Text |b txt |2 rdacontent | ||
| 337 | |a ƒaComputermedien |b c |2 rdamedia | ||
| 338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
| 500 | |a Date Revised 12.04.2024 | ||
| 500 | |a published: Print-Electronic | ||
| 500 | |a Citation Status PubMed-not-MEDLINE | ||
| 520 | |a 2024 Translational Lung Cancer Research. All rights reserved. | ||
| 520 | |a Background: Hyperprogressive disease is an unexpected response pattern observed in immune checkpoint therapy and associated with poor prognosis. The rechallenge of programmed cell death 1/programmed cell death ligand 1 (PD-1/PD-L1) inhibitors can be a treatment option in non-small cell lung cancer (NSCLC) patients who once responded to them. Here, we reported the hyperprogressive phenomenon after PD-1/PD-L1 rechallenge in a patient with NSCLC | ||
| 520 | |a Case Description: This case report described a patient with recurrent large cell lung cancer undergoing hyperprogressive disease with pleural and pericardial dissemination shortly after the pembrolizumab rechallenge, although he had a favorable response to the initial pembrolizumab treatment. A lower ratio of CD8+ T cells to Foxp3+ regulatory T cells was distributed in the cell blocks of pleural and pericardial effusion which were taken after hyperprogressive disease, compared to the resected tumor microenvironment. Neutrophil-to-lymphocyte ratio (NLR) was lower in peripheral blood when the disease was controlled and it rose when the disease progressed. Notably, NLR increased dramatically when hyperprogression occurred | ||
| 520 | |a Conclusions: For the first time, we reported that a patient who showed a favorable response to initial anti-PD-1 treatment underwent hyperprogressive disease when rechallenging the same immunotherapy. The increased Foxp3+ regulatory T cells in the tumor microenvironment and the longitudinal change of NLRs in peripheral blood were suggested to be associated with hyperprogressive disease | ||
| 650 | 4 | |a Case Reports | |
| 650 | 4 | |a Foxp3+ regulatory T cells | |
| 650 | 4 | |a Non-small cell lung cancer (NSCLC) | |
| 650 | 4 | |a anti-programmed cell death 1 rechallenge (anti-PD-1 rechallenge) | |
| 650 | 4 | |a case report | |
| 650 | 4 | |a hyperprogressive disease | |
| 700 | 1 | |a Shukuya, Takehito |e verfasserin |4 aut | |
| 700 | 1 | |a Shimamura, Shoko |e verfasserin |4 aut | |
| 700 | 1 | |a Hayashi, Takuo |e verfasserin |4 aut | |
| 700 | 1 | |a Sato, Yoshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Shiozaki, Hitomi |e verfasserin |4 aut | |
| 700 | 1 | |a Nishioki, Toshihiko |e verfasserin |4 aut | |
| 700 | 1 | |a Nishino, Koichi |e verfasserin |4 aut | |
| 700 | 1 | |a Kato, Motoyasu |e verfasserin |4 aut | |
| 700 | 1 | |a Hattori, Aritoshi |e verfasserin |4 aut | |
| 700 | 1 | |a Shimada, Naoko |e verfasserin |4 aut | |
| 700 | 1 | |a Suzuki, Kenji |e verfasserin |4 aut | |
| 700 | 1 | |a Kitano, Shigehisa |e verfasserin |4 aut | |
| 700 | 1 | |a Takahashi, Kazuhisa |e verfasserin |4 aut | |
| 773 | 0 | 8 | |i Enthalten in |t Translational lung cancer research |d 2012 |g 13(2024), 3 vom: 29. März, Seite 666-672 |w (DE-627)NLM24739839X |x 2218-6751 |7 nnns |
| 773 | 1 | 8 | |g volume:13 |g year:2024 |g number:3 |g day:29 |g month:03 |g pages:666-672 |
| 856 | 4 | 0 | |u http://dx.doi.org/10.21037/tlcr-23-765 |3 Volltext |
| 912 | |a GBV_USEFLAG_A | ||
| 912 | |a GBV_NLM | ||
| 951 | |a AR | ||
| 952 | |d 13 |j 2024 |e 3 |b 29 |c 03 |h 666-672 | ||